Progress, Potential, and Possibilities Podcast / Show Prof. Dr. Thomas Rademacher, MD, PhD - CEO & Co-Founder, Emergex - T-Cell Priming Immunotherapies To Provide Broad And Robust, Long-Term Immunity
Professor Dr. Thomas Rademacher, MD, PhD, is CEO and Co-Founder of Emergex ( https://emergexvaccines.com/ ), a company that has developed a novel nanoparticle-based vaccine technology to deliver synthetic viral fragments via microneedles on a skin-adhesive patch. Emergex’s approach works on the principle of priming immune T-cells, opening the door for the development of universal vaccines against highly mutagenic viruses such as the seasonal flu and covid. T-cell priming offers a superior inoculation strategy over traditional vaccines, which rely on the body’s generation of antibodies and fail to keep up with seasonal mutations. A serial entrepreneur, Professor Rademacher also serves as Emeritus Professor of Molecular Medicine at University College London (UCL) and is widely considered one of the founders of biotech from the early 1980s (having been involved in many of it’s core disciplines – from recombinant proteins, to monoclonal antibodies, to glycobiology). Professor Rademacher has authored over 200 publications and 50 patents – 19 of which are in the nanomedicine field. In addition to being a world leader in nanomedicine, he is also an expert in fetal-maternal medicine, having produced 25 publications and filed 5 patents related to preeclampsia. Professor Rademacher was co-Founder of the field of Glycobiology and subsequent Glycobiology Institute in Oxford and co-founded Oxford GlycoSciences, the first of Oxford University’s biotech spinouts, which, in 1998, was listed on the London Stock Exchange and reached a market capitalization of £1.7 billion. After moving to UCL, Professor Rademacher founded several biotech spin-out companies, including Rodaris Pharmaceuticals Ltd. In 2000, Professor Rademacher entered into a collaboration with the Spanish Research Council and co-founded the first nanomedicine company, Midatech Ltd. Midatech floated on the AIM and NASDAQ stock exchanges in December 2015.